Nevertheless, we suppose that HGSOC patients with high MEK/ERK activity and COMS genes expression in tumor tissue may benefit from MEK1/2 inhibition, as it may prevent platinum resistance development in the course of initial treatment. The gene discussed is MAP2K1; the disease is neoplasm.